Scenario Please read this scenario prior to answering the Question You are serving as the
Lead Architect for an enterprise architecture project team within a leading multinational
pharmaceutical and medical devices manufacturer. Its brands include numerous household
names for medications and first aid supplies. The company has a long history of innovating
new treatments for many common illnesses and diseases. Prior to launching a new
treatment, the company has to demonstrate Its effectiveness and safety in a set of clinical
trials that satisfy the regulatory requirements of the countries in the target markets. All
clinical trials are undertaken by its research laboratories, which employ over 10,000 people
at separate facilities in the United Kingdom, United States, Sweden, France, Canada, India,
China and Japan. In addition to internal research and development activities the company is
also involved in publicly funded collaborative research projects, with other industrial and
academic partners. The Enterprise Architecture group within the company has been
engaged in an architecture development project to create a secure networked collaboration
system that will allow researchers at its product development laboratories worldwide to
share information about their clinical trials. This system will also connect with external
partners. The Enterprise Architecture group within the company has been engaged in an
architecture development project to create a secure networked collaboration system that will
allow researchers at its product development laboratories worldwide to share information
about their clinical trials. This system will also connect with external partners. The
Enterprise Architecture group is a mature organization. They use the TOGAF 9 ADM with
extensions required to support current good manufacturing practices and good laboratory
practices in their target markets. Due to the highly sensitive nature of the information that is
managed, special care was taken to ensure that each architecture domain included an
examination of the security and privacy issues that are relevant. The Executive Vice
President for Clinical Research is the sponsor of the Enterprise Architecture activity. She
has stated that the changes to the enterprise architecture for the new system will need to be
rolled out in stages on a regional basis that minimizes disruptions to ongoing clinical trials.
Refer to the Scenario You have been asked to recommend the approach to identify the
work packages that will be included in the Transition Architecture(s). Based on TOGAF,
which of the following is the best answer?

A.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated
Gaps, Solutions and Dependencies Matrix. For each gap, identify a proposed solution and

classify it as new development, purchased solution, or based on an existing product. Group
similar solutions together to form work packages. Identify dependencies between work
packages factoring in the clinical trial schedules. Regroup the packages into a set of
Capability Increments scheduled into a series of Transition Architectures.

B.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and
Dependencies Matrix into a set of work packages. Using the matrix as a planning tool,
regroup the work packages to account for dependencies. Sequence the work packages into
the Capability Increments needed to achieve the Target Architecture. Schedule the rollout
one region at a time. Document the progression of the enterprise architecture using a state
evolution table.

C.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For
each gap classify whether the solution is either a new development, purchased solution, or
based on an existing product. Group the similar solutions together to define the work
packages. Regroup the work packages into a set of Capability Increments to transition to
the Target Architecture taking into account the schedule for clinical trials.

D.
Determine the set of Solution Building Blocks required by identifying which Solution
Building Blocks need to be developed and which need to be procured. Eliminate any
duplicate building blocks. Group the remaining Solution Building Blocks together to create
the work packages using a CRUD matrix. Rank the work packages in terms of cost and
select the most cost-effective options for inclusion in a series of Transition Architectures.
Schedule the roll out of the work packages to be sequential across the geographic regions.